Request Demo

Last update 13 Aug 2026

Albumin-Bound Paclitaxel

Last update 13 Aug 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Nab-Paclitaxel, Nab-PTX, Paclitaxel Albumin Nanoparticles

+ [19]

Target

Tubulin

Action

inhibitors

Mechanism

Tubulin inhibitors

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [8]

Active Indication

Advanced breast cancerNeoplasmsMetastatic Pancreatic Cancer+ [43]

Inactive Indication

Adenocarcinoma of large intestineAdenocarcinoma of small intestineAdenosquamous Carcinoma+ [109]

Originator Organization

CSPC Pharmaceutical Group Ltd.

Abraxis BioScience, Inc.

Active Organization

Teva Pharmaceuticals, Inc.Hoffmann-La Roche, Inc.

Kexing Biopharm Co., Ltd.

+ [15]

Inactive Organization

Daiichi Sankyo Co., Ltd.

Amgen, Inc.Roche Pharma AG

+ [13]

License Organization

Zhejiang Haichang Bio-Tech Co., Ltd.

BeOne Medicines Ltd.

Kexing Biopharm Co., Ltd.

+ [8]

Drug Highest PhaseApproved

First Approval Date

United States (07 Jan 2005),

Metastatic breast cancer

Regulation-

Structure/Sequence

Molecular FormulaC47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS Registry33069-62-4

2,817

Clinical Trials associated with Albumin-Bound Paclitaxel

NCT06592664

/ WithdrawnPhase 1/2

A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

Start Date01 Jan 2030

Sponsor / Collaborator

Lisata Therapeutics, Inc.

NCT07748611

/ Not yet recruitingPhase 2IIT

SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study

This phase II trial tests the impact of using SMAD4-mutant status to personalize chemotherapy in treating patients with pancreatic ductal adenocarcinoma (PDAC) that can be removed by surgery (resectable) or that may be between resectable and unresectable (borderline resectable) before undergoing surgery (neoadjuvant). PDAC is one of the most aggressive and fastest growing tumors. SMAD4, a tumor suppressor gene, acts like a brake on cell growth and helps to prevent tumor cells from growing. However, losing it makes the tumor more aggressive and often resistant to standard of care (SOC) treatments regimens, such as gemcitabine with nab-paclitaxel and fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic (DNA) and may kill tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Fluorouracil, a type of antimetabolite, stops cells from making DNA and it may kill tumor cells. Leucovorin is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Instead of a one-sized fits all treatment approach with SOC therapies, matching therapy based on SMAD4 mutation status may use this specific genetic weakness against the tumor. This approach to neoadjuvant therapy may dramatically alter the path of treatment and improve outcomes, including complete resection rates, in patients with resectable or borderline resectable PDAC.

Start Date03 Feb 2027

Sponsor / Collaborator

Northwestern University

[+1]

NCT07610525

/ Not yet recruitingPhase 2

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Tria

To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.

Start Date05 Nov 2026

Sponsor / Collaborator-

100 Clinical Results associated with Albumin-Bound Paclitaxel

100 Translational Medicine associated with Albumin-Bound Paclitaxel

100 Patents (Medical) associated with Albumin-Bound Paclitaxel

25,176

Literatures (Medical) associated with Albumin-Bound Paclitaxel

31 Dec 2026·Future Science OA

Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer

Article

Author: Su, Zhimin ; Li, Zhiyong ; Shen, Feng ; Jiang, Jiana

OBJECTIVE:

We aim to compare the clinical efficacy and safety of albumin-bound paclitaxel (nab-PTX) (125 mg/m2, q2w) for two weeks and (125 mg/m2, d1, d8, q3w) for three weeks in the first-line treatment of advanced pancreatic cancer.

METHODS:

The medical records of patients with advanced pancreatic cancer who received nab-PTX for 2 weeks and 3 weeks, combined with gemcitabine, from July 2018 to January 2023, were retrospectively analyzed. The efficacy and adverse reactions of the two groups of patients were compared.

RESULT:

A total of 64 patients were included. The median progression-free survival (mPFS) of the 2-week group was 5.6 months, while the 3-week group was 7.8 months. The median overall survival (mOS) of the 2-week group was 14.0 months, while the 3-week group was 14.7 months. The multivariate analysis showed that a physical fitness status score of 0-1 was an independent factor with better OS, while metastatic sites ≥ 3 were related to poor OS. The incidence of leukopenia or neutropenia, neurotoxicity, fatigue, and poor appetite in the 2-week group was lower than that in the 3-week group.

CONCLUSION:

The clinical efficacy of nab-PTX in the 2-week and dose intensive 3 week did not show significant difference, but the 2-week treatment group had better tolerance and safety.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report

Article

Author: Zhuang, Yihan ; Chen, Qiongshan ; Lin, Wen ; Chen, Zipei

Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

31 Dec 2026·DRUG DELIVERY

The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity

Article

Author: Jiang, Chengwei ; Schätzlein, Andreas G. ; Uchegbu, Ijeoma F. ; Xiong, Guojun

Human serum albumin (HSA) has attracted significant attention in drug delivery since the approval of Abraxane in 2005. Abraxane is a nanoparticle albumin-bound paclitaxel (nab-PTX) formulation. Although HSA offers advantages such as prolonged circulation time (half-life ~19 days) and intrinsic hydrophobic pockets, the translation of other HSA-based nanomedicines remains limited. In fact, the significant differences between native and pharmaceutical HSA in protein structure and biological interactions could hinder their translational use in drug delivery. In this study, we demonstrate that pharmaceutical HSA (α-helix = 17%) is structurally denatured compared with native HSA (α-helix = 68%), leading to rapid clearance (<1 h) from the circulation and that drug loading is driven by pharmaceutical HSA's amphiphilicity rather than by its hydrophobic pockets. Here, we revealed that Nab-PTX is composed of protein-coated PTX solid cores. These nanosystems have insufficient surface charge (ζ = -13.7 mV), leading to aggregation, and low colloidal stability, resulting in premature drug release upon dilution (<0.1 mg/mL). To address these shortcomings, we developed HSA-polylactic acid (HSA-PLA) nanoparticles with enhanced negative surface charge (ζ = -27.4 mV) and improved colloidal stability to reduce the premature release of encapsulated PTX upon dilution (<0.01 mg/mL). In tumor models, comparative pharmacokinetics, biodistribution, and efficacy studies demonstrated that HSA-PLA (PTX) nanoparticles reduce premature drug release, resulting in greater tumor exposure (129 ± 3 vs. 90 ± 12 µg·h/g, p < 0.01) and superior antitumor efficacy compared with Abraxane. These improvements further suggest that optimization may require only a simple modification when guided by proper theoretical principles.

1,124

News (Medical) associated with Albumin-Bound Paclitaxel

12 Aug 2026

·www.biospace.com

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Contrasting Science with Revolution Medicines and Erasca MELBOURNE, Australia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today provided a scientific comparison of its lead candidate PRP with the RAS-targeted approaches of Revolution Medicines, Inc. and Erasca, Inc. The Company articulates why PRP’s unique mechanism—promoting cancer cell differentiation, reversing epithelial-mesenchymal transition (EMT), and targeting cancer stem cells via pancreatic proenzymes—positions it as a potential long-term therapy of choice, particularly for aggressive, treatment-resistant cancers such as pancreatic ductal adenocarcinoma (PDAC). “As we enter a world first clinical study for the use of our lead asset, PRP, as a novel way to combat PDAC but also aggressive, less differentiated tumor types often associated with a poor patient prognosis, we felt it was an important opportunity to highlight that we are entering a transformative phase for these killer diseases which is unprecedented,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “Recent advances by Revolution Medicines and Erasca Inc. are tremendously exciting, but further improvements can be made with complementary treatment modalities such as PRP that target the way cancer cells become malignant, invasive and spread. PRP is a novel therapy that targets these dangerous cells but leaves healthy cells intact. Therefore, it is not cytotoxic. It does not involve an inhibitory approach which often leads to drug resistance, but proteolysis (protein breakdown) is the basis for enforcing cancer cells to express certain pathways that induce differentiation so that they return to a normal state and die naturally. We expect to clinical trial application for the Phase 1b clinical study in advanced cancer patients in Q4 this year and are confident of replicating the successful peer reviewed, published results obtained in preclinical models and clinical observations from terminal patients treated at much lower doses for up to 18 months in a previous compassionate use study. We look forward to generating meaningful data demonstrating PRP as a long-term treatment option for metastatic cancer from solid tumors.” Propanc's Science: Proenzyme-Driven Differentiation and Metastasis Suppression ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); PRP is a proprietary fixed-ratio combination of pancreatic proenzymes trypsinogen and chymotrypsinogen, administered once weekly by intravenous injection. Unlike cytotoxic agents or pathway inhibitors that directly kill dividing cells or block signaling, PRP activates upon administration to induce differentiation of malignant cells toward a more normal phenotype (cellular characteristics). Key effects include: Reversal of EMT, reducing invasive and stem-like properties of cancer cells. Suppression of metastasis, angiogenesis, and tumor microenvironment support (including effects on cancer-associated fibroblasts). Enhanced cell adhesion and promotion of natural cell death pathways. Favorable preclinical activity: >90%, mean tumor growth inhibition in orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, marked reduction in metastatic burden (liver and peritoneum), and >2.5-fold extension of median overall survival versus controls (p < 0.001). PRP has also shown potential to resensitize chemo-resistant PDAC cells to standard agents such as gemcitabine/nab-paclitaxel at lower doses. PRP holds FDA Orphan Drug Designation for pancreatic cancer. Limited prior compassionate-use experience with related proenzyme formulations showed signals of prolonged survival in advanced solid-tumor patients without severe treatment-related adverse events. The Company is advancing toward a Phase 1b first-in-human study in up to 40 – 45 patients with advanced solid tumors (focus on PDAC and other high-unmet-need indications), with GMP manufacturing and clinical partnerships progressing in 2026. Revolution Medicines (RVMD): RAS(ON) Tri-Complex Inhibitors RVMD develops a portfolio of RAS(ON) inhibitors that target the active, GTP-bound state of mutant (and in some cases wild-type) RAS proteins via a cyclophilin A tri-complex mechanism. Lead assets include daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor; allele-selective inhibitors such as zoldonrasib (RMC-9805, G12D-selective) and others targeting G12C and G12V; and emerging catalytic RAS(ON) approaches designed to stimulate GTP hydrolysis. These agents block RAS-effector interactions, suppress downstream MAPK and other signaling, and have demonstrated robust preclinical and clinical activity, including statistically significant overall survival and progression-free survival benefits versus chemotherapy in previously treated metastatic PDAC (e.g., Phase 3 RASolute 302 data for daraxonrasib). They address a major oncogenic driver present in ~90%+ of PDAC, substantial fractions of NSCLC and colorectal cancer, and other RAS-addicted tumors. Limitations can include pathway reactivation/resistance mechanisms, on-target effects on wild-type RAS in normal tissues, and the need for continuous pathway suppression Erasca (ERAS): RAS/MAPK Pathway Clamping and Direct RAS Targeting Erasca focuses on the RAS/MAPK pathway with a modality-agnostic strategy. Key approaches include MAPKlamp (upstream SHP2 and downstream ERK inhibition to “clamp” signaling), direct RAS targeting via pan-RAS molecular glues such as ERAS-0015 (which forms a ternary complex with cyclophilin A and active RAS to block effector engagement), pan-KRAS inhibitors, and agents addressing escape routes (e.g., EGFR). ERAS-0015 has shown early clinical signals of antitumor activity in RAS-mutant solid tumors, including encouraging unconfirmed response rates in KRAS G12X NSCLC and PDAC cohorts, with pharmacodynamic evidence of target engagement (ctDNA reductions). The pipeline aims for broad coverage of RAS/MAPK alterations and resistance mechanisms. Like other targeted pathway inhibitors, challenges include incomplete pathway shutdown, adaptive resistance, and managing toxicity from multi-node inhibition. Comparison and Contrast Aspect Propanc (PRP) RVMD (RAS(ON) inhibitors) Erasca (MAPKlamp / pan-RAS glues) Primary Target Cancer stem cells, EMT, differentiation Active RAS(ON) proteins RAS/MAPK nodes (SHP2, ERK, RAS itself) Mechanism Proenzyme-induced phenotypic reprogramming; metastasis suppression Steric blockade of RAS-effector binding via tri-complex Pathway clamping or molecular glue inhibition of RAS signaling Breadth Solid tumors broadly (stem-like/metastatic phenotype); not mutation-specific RAS-mutant cancers (multi- or allele-selective) RAS/MAPK-altered cancers Toxicity Profile Favorable in limited human experience; non-cytotoxic Manageable but on-target pathway effects Generally well-tolerated in early data; multi-node considerations Resistance Risk Targets upstream biology of aggressiveness rather than single pathway Pathway reactivation / bypass possible Escape routes actively addressed but still pathway-dependent Administration Once weekly IV Oral (daily) Oral Stage Preclinical/translational → Phase 1b FIH planned Late-stage clinical / NDA pathway for some assets Early-to-mid clinical RVMD and Erasca represent important advances in directly targeting the long, “undruggable” RAS oncogene and its downstream pathway—addressing a core driver of many solid tumors. Their science is highly complementary to conventional chemotherapy and emerging combinations. However, both remain fundamentally pathway-centric: they suppress oncogenic signaling but do not inherently reverse the stem-like, mesenchymal, metastatic phenotype that drives recurrence and treatment failure, especially in PDAC and other aggressive cancers. Propanc’s PRP operates at a different biological layer. By promoting differentiation and reversing EMT, it aims to reduce the reservoir of cancer stem cells responsible for resistance, dormancy, and dissemination. Preclinical data showing high tumor growth inhibition, metastatic burden reduction, survival extension, and potential chemo-sensitization support the hypothesis that PRP could serve as a backbone or sequential therapy—potentially enhancing durability when combined with RAS pathway inhibitors or used in maintenance settings where chronic, low-toxicity treatment is desirable. Why PRP Could Prove the Therapy of Choice For patients with advanced or high-risk solid tumors – particularly those with limited options after progression on chemotherapy or targeted agents – PRP’s pro several potential advantages: Non-cytotoxic, a differentiation-based approach that may spare normal tissues while addressing the root drivers of metastasis and recurrence. Broad applicability across solid tumors (80–90% of cancers) without requiring specific RAS mutations. Favorable tolerability supporting long-term or intermittent use, critical for preventing relapse. Synergy potential with existing standards of care and emerging RAS inhibitors (chemo-sensitization data already observed). Orphan designation and focused development in PDAC, an indication with profound unmet need where both RVMD and Erasca are also active. Propanc believes that while RAS(ON) and RAS/MAPK-targeted agents will transform outcomes for many patients by hitting the oncogenic switch, therapies that reprogram the malignant phenotype itself may ultimately deliver more durable control and improved quality of life. As PRP advances into the clinic, the Company looks forward to generating human data that will further clarify its role—potentially as a foundational, long-term option in the evolving treatment landscape for metastatic solid tumors. About Propanc Biopharma, Inc. Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread. More information: Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available. Company: Propanc Biopharma, Inc. James Nathanielsz +61-3-9882-0780 info@propanc.com Investor Contact: irteam@propanc.com

Phase 1Orphan DrugClinical ResultPhase 3

12 Aug 2026

·ir.renovorx.com

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III TIGeR-PaC Trial Reaches Full Enrollment; Completion of Trial Expected in First Half 2027 with Topline Data Readout Expected in Second Half 2027 Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its financial results for the second quarter ended June 30, 2026, and provided shareholders with a business update highlighting continued commercial momentum and clinical progress. “In the second quarter of 2026, we delivered record revenue and executed on all three of the milestones we set for the business: revenue growth with another record revenue quarter, commercial momentum evidenced by several cancer center activations, and expansion of the application of our technology beyond locally advanced pancreatic cancer (LAPC),” said Shaun Bagai, Chief Executive Officer of RenovoRx. “We generated quarterly revenue of $909,000, an increase of approximately 61% compared to the first quarter of 2026, and approximately 115% compared to the second quarter of 2025. Our strong first half performance gives us confidence that our second half revenue will exceed our original full year forecast. This outlook is driven by more active commercial cancer center customers, more patients treated via procedures with RenovoCath, and repeat ordering across our existing customer base.” Mr. Bagai continued, “We ended the second quarter with 21 active commercial cancer center customers, an increase of more than 30% from the 16 centers reported at the time of our first quarter earnings call, and expanded our total commercial pipeline to 63 centers, including 42 additional centers progressing through evaluation, approval, and activation. We continue to see meaningful repeat utilization across our existing customer base, and for the first time, a treating physician chose RenovoCath to deliver therapy to a patient with a solid tumor beyond pancreatic cancer, marking an important, physician-driven expansion of the clinical application of our TAMP platform.” “Looking ahead, we remain focused on executing against both our near-term commercial priorities and our long-term clinical objectives,” added Mr. Bagai. “Based on current trends, we expect third quarter revenue to surpass second-quarter revenue and set another record. We remain on track to meet or exceed our target of 36 active commercial cancer center customers by year end 2026." "The recently announced enrollment completion of our Phase III TIGeR-PaC trial positions the majority of our trial sites to also transition to commercial use in the second half of the year. Reflecting our strong first half performance, we are raising and tightening the range for our full year revenue guidance. In short, we believe RenovoRx is building a durable, capital-efficient commercial business," said Mr. Bagai. "Management believe that reaching a quarterly revenue run-rate of approximately $5 million would position RenovoRx at cash-flow break-even, and based on our current trajectory, our internal plan anticipates achieving break-even operations in the fourth quarter of 2027." RenovoCath Commercialization UpdateRenovoRx delivered its strongest quarterly revenue performance to date. Revenue totaled $909,000 for the second quarter, an increase of approximately 61% compared to the first quarter of 2026 and approximately 115% compared to the second quarter of 2025. Second quarter revenue alone represented approximately 83% of the Company’s total revenue generated in all of 2025. For the six months ended June 30, 2026, revenue totaled approximately $1.5 million. This growth reflects continued expansion of active commercial cancer center customers and increasing procedural utilization of RenovoCath across the Company’s growing base of commercial sites. The Company’s commercial model is currently focused on activating new cancer center customers, which have been a source of recurring demand. RenovoRx ended the second quarter of 2026 with 21 active commercial cancer center customers, an increase of more than 30% from the 16 active customers reported at the time of the Company’s first quarter 2026 earnings call. RenovoRx is also advancing a customer pipeline of 42 additional centers in various stages of evaluation, approval, or activation. Combined with its 21 active customers, this represents a total of 63 centers in the Company’s commercial funnel, a 31% increase compared to the 48 total centers reported on its first quarter call. The Company remains on pace to meet or exceed its target of 36 active commercial cancer center customers by year end 2026. In addition, 15 Phase III TIGeR-PaC clinical trial sites are positioned to transition to commercial RenovoCath use, several of which have already begun doing so. These sites represent an anticipated and meaningful contributor to revenue in the second half of 2026. RenovoRx continues to observe strong repeat ordering from existing customers, which the Company views as one of the clearest indicators of physician satisfaction and clinical utility in interventional oncology. As physicians incorporate RenovoCath into routine clinical practice, repeat utilization is expected to drive sustained revenue growth. Based on its current customer pipeline and trends to date, the Company expects third quarter 2026 revenue to exceed second quarter revenue which would represent another consecutive record revenue quarter. Since receiving FDA 510(k) clearance, RenovoCath has been used in more than 900 successful procedures. RenovoRx continues to estimate that the initial total addressable market (TAM) for RenovoCath as a stand-alone device could translate into an approximately $400 million peak annual U.S. sales opportunity for RenovoRx. Over time, as the Company expands the platform into additional solid tumor indications, the Company believes it could unlock more than $1 billion in peak annual sales potential. Expansion of RenovoCath Beyond Locally Advanced Pancreatic CancerIn early August 2026, RenovoRx announced the first commercial clinical use of RenovoCath by an existing cancer center customer in the treatment of sarcoma, marking the expansion of its targeted drug-delivery device to solid tumors beyond pancreatic cancer. The case involved a physician who had previously treated LAPC patients using RenovoCath and returned to RenovoRx with a plan to use the catheter to treat sarcoma. The Company views this physician-driven adoption as a meaningful endorsement of RenovoCath’s potential as a standalone device across additional difficult-to-treat solid tumors within its FDA-cleared fields of use. Ongoing Phase III TIGeR-PaC Trial UpdateRecently, RenovoRx announced that it achieved full enrollment in its Phase III TIGeR-PaC trial evaluating intra-arterial delivery of intra-arterial gemcitabine (IAG) via the RenovoCath device for the treatment of LAPC. This significant milestone reflects successful patient recruitment, clinical execution, and collaboration among investigators and study teams evaluating IAG for LAPC, a difficult-to-treat cancer. The primary endpoint of the study is overall survival. TIGeR-PaC is designed to evaluate whether RenovoRx’s patented method of targeted delivery of the chemotherapy gemcitabine improves patient survival, safety, and tolerability compared to the standard of care (systemic (intravenous) chemotherapy gemcitabine + Abraxane). As of August 7, 2026, TIGeR-PaC trial investigators have been notified by RenovoRx that patient enrollment is closing. Completion of the trial is expected during the first half of 2027, after 86 events (i.e., patient deaths) have been observed. As of August 11, 2026, 78 events have occurred. Following completion of the trial, initial topline trial data is expected to be available during the second half of 2027. With enrollment complete, RenovoRx is now focused on advancing toward final data analysis. These efforts build on the successful completion of the second interim analysis in 2025, after which the independent Data Monitoring Committee recommended continuation of the trial without modification. To preserve trial integrity, the Company elected to defer publication of interim data until study completion. RenovoRx continues to view TIGeR-PaC as a critical long-term value driver, while emphasizing that its current commercial strategy is independent of the trial’s ultimate outcome and timeline. Second Quarter 2026 and Subsequent Key HighlightsRenovoRx continued to execute on its dual commercial and clinical strategy during the second quarter of 2026 and the subsequent period, building real-world evidence base for its TAMP platform. During the second quarter of 2026, several scientific data updates supported the use of intra-arterial gemcitabine delivery via TAMP in LAPC. A peer-reviewed case study by researchers at Moffitt Cancer Center, published in Radiology Case Reports, found that PET-CT imaging, rather than CT alone, showed a meaningful reduction in tumor metabolic activity after treatment. These findings suggest that PET imaging may help optimize monitoring of therapeutic response following TAMP-delivered treatment. In addition, the PK sub-study of the TIGeR-PaC trial has been accepted and will be published in the near future in the Journal of Cancer Chemotherapy and Pharmacology. The findings support TAMP as a targeted delivery method for gemcitabine, demonstrating its potential to increase local drug potency while reducing systemic exposure and common side effects. Finally, a peer-reviewed case series in Case Reports in Oncology from researchers at Hackensack Meridian Health’s Jersey Shore University’s Medical Center was accepted and will be published in the near future. The case series highlights their experience with the TAMP procedure in LAPC. The ramping up of publication of the TAMP procedure by physicians, the Company believes is another sign of adoption as TAMP traverses from an experimental procedure to becoming a potential standard of care. Cash Resources, History of Losses and Planned ActivitiesRenovoRx continued to build the evidence base for its TAMP platform through a multi-center post-marketing registry study generating real-world safety and efficacy data, as well as investigator-initiated trials (IITs) in borderline resectable and metastatic pancreatic cancer designed to achieve cost neutrality while broadening the platform’s evidence base. In the second quarter of 2026, the Company began supporting a new IIT in cholangiocarcinoma (bile duct cancer). RenovoRx received FDA Orphan Drug Designation for oxaliplatin in the treatment of pancreatic cancer in the second quarter of 2026, further expanding the potential applications of its targeted drug-delivery platform. Financial Highlights for the Second Quarter Ended June 30, 2026 Revenue for the three months ended June 30, 2026 was $909,000, compared to $422,000 for the three months ended June 30, 2025. The increase was driven by the continued commercialization of RenovoCath and expanding adoption across U.S. cancer centers. Gross profit for the three months ended June 30, 2026 was $766,000, representing a gross margin of approximately 84%, consistent with the approximately 85% gross margin in the first quarter of 2026 and reflecting the underlying economics of RenovoCath. Research and development expenses were approximately $1.2 million for the three months ended June 30, 2026, compared to approximately $1.4 million for the three months ended June 30, 2025. Selling, general, and administrative expenses were approximately $2.9 million for the three months ended June 30, 2026, compared to approximately $1.5 million for the three months ended June 30, 2025, a reflection of the Company’s continued execution on its commercial infrastructure strategy. Net loss for the three months ended June 30, 2026, was approximately $2.9 million, compared to approximately $2.9 million for the three months ended June 30, 2025. Net loss per share was $0.06 for the three months ended June 30, 2026, compared to a net loss of $0.08 for the three months ended June 30, 2025. Cash and cash equivalents were approximately $9.5 million as of June 30, 2026, compared to approximately $12.4 million as of March 31, 2026. This evidences the disciplined deployment of capital raised in the Company’s March 2026 private placement. The Company believes its current cash resources are sufficient to fund operations into the second half of 2027. Shares Outstanding: As of June 30, 2026, common shares outstanding totaled 45,121,982. Guidance: RenovoRx is raising and tightening the range of its full-year 2026 revenue guidance to a range of $3.75 million to $4.25 million, from its prior range of $3.0 million to $4.0 million. The updated guidance implies year-over-year revenue growth of approximately 241% to 286% compared to full-year 2025 revenue of $1.1 million. For interested individuals unable to join the conference call, a link to the recording will be available on RenovoRx’s Investor Relations website, and a dial-in replay will be available until August 26, 2026, and can be accessed by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International) and entering replay pin number 13761368. A question and answer session will occur at the end of the call, and a link to the recording of this presentation will be available on RenovoRx’s Investor Relations website after the event. About RenovoCathBased on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: https://renovorx.com/wp-content/uploads/2026/06/IFU-10004-Rev.-H-Universal-IFU.pdf. About RenovoRx, Inc.RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a standalone device. For its first full year of commercial efforts in 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales and a record $563,000 of sales in the first quarter of 2026. RenovoRx is actively working to expand the number of medical institutions initiating new RenovoCath orders, including esteemed, high-volume National Cancer Institute-designated centers. RenovoRx is also evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath, (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, which is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx achieved full enrollment in the TIGeR-PaC trial in August 2026, with completion of trial expected in first half 2027 and with topline data readout expected in second half 2027. The IAG combination product candidate, enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA. For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X. Non-GAAP Financial MeasuresIn addition to reporting financial results in accordance with U.S. generally accepted accounting principles (“GAAP”), the operating results presented in the accompanying tables include certain non-GAAP financial measures that exclude the non-cash expense associated with share-based compensation. We are providing such non-GAAP financial information in this press release, including non-GAAP operating expenses, net income (loss), and earnings (loss) per share, as a supplement to our consolidated financial statements prepared in accordance with GAAP which appear in this press release and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 as filed with the U.S. Securities and Exchange Commission. Our management uses these non-GAAP measures internally to analyze financial results, evaluate operational performance, and assess liquidity. We believe that both management and investors benefit from referring to these non-GAAP measures when assessing performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP measures also enhance investors’ understanding of key financial metrics used in operational decision-making and are useful for comparing our performance to that of other companies. However, readers are cautioned that non-GAAP results are presented for supplemental information purposes only and should not be considered a substitute for GAAP financial information. These measures may differ from similarly titled non-GAAP measures presented by other companies. Moreover, non-GAAP financial measures are not required to be uniformly applied and are not audited. Cautionary Note Regarding Forward-Looking StatementsThis press release and statements of the Company’s management and third parties made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies (including expectations for full enrollment and data read out), (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and TAMP technology for use in treating pancreatic and other solid tumor cancers, and our expected financial results from such efforts, including our estimates for 2026 annual revenue. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, commercial and other business plans, intellectual property development, clinical trials, our therapy platform, financing plans, objectives, and expected operating results, all of which are based on current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “aim,” “goal,” “estimates,” “intends,” and “potential,” or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about the future, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial efforts our TAMP technology (enabled by RenovoCath) may not lead to the achievement of our revenue forecasts or to viable, revenue generating operations in general; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress, completion and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs (notably with respect to our TIGeR-PaC trial); (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our ability to obtain additional capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xviii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission, which can be accessed at https://ir.renovorx.com/sec-filings. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law. Investor Contact:KCSA Strategic CommunicationsValter Pinto or Jack PerkinsT: 212-896-1254RenovoRx@KCSA.com Media Contact:STiR CommunicationsHannah WilliamsT: 803-521-1214hannah@stir-communications.com Released August 12, 2026

Phase 3Orphan DrugFinancial StatementDrug Approval

11 Aug 2026

·www.biospace.com

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

Completion of Trial Expected in First Half 2027 With Topline Data Readout Expected Second Half 2027 MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, is pleased to announce completion of enrollment in the Company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC). As of August 7, 2026, TIGeR-PaC trial investigators have been notified by RenovoRx that patient enrollment is closing. Completion of the trial is expected during the first half of 2027, after 86 events (i.e., patient deaths) have been observed. As of August 11, 2026, 78 events have occurred. Following completion of the trial, initial top line trial data is expected to be available during the second half of 2027. This significant milestone reflects successful patient recruitment, clinical execution, and collaboration among investigators and study teams evaluating intra-arterial gemcitabine (IAG) via RenovoCath delivered through RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) platform as a novel drug-device product candidate for difficult-to-treat LAPC. The primary endpoint of the study is overall survival. TIGeR-PaC is designed to evaluate whether RenovoRx’s patented method of targeted delivery of the chemotherapy gemcitabine improves patient survival, safety, and tolerability compared to the standard of care (systemic (intravenous) chemotherapy gemcitabine + Abraxane). ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Pancreatic cancer continues to represent a major unmet medical need, with limited treatment options and current standards of care centered largely on systemic chemotherapy, which can cause significant toxicity and related side effects for patients. TAMP is designed to deliver chemotherapy directly near the tumor site while potentially reducing systemic exposure. “The TIGeR-PaC Phase III study represents an exciting step forward in the treatment of LAPC,” said Hassan Hatoum, MD Associate Professor of Medicine Medical Director, GI Oncology Disease Site Chair, GI Oncology Disease Site Group Stephenson Cancer Center University of Oklahoma Health Sciences Center and principal investigator at the University of Oklahoma Health for the TIGeR-PaC trial. “For far too long, patients with LAPC have had limited options beyond systemic chemotherapy. This novel treatment approach offers hope by adding an innovative, locoregional and targeted intervention that has the potential to improve outcomes beyond the current standard of care. The preliminary results of this study have been encouraging and reinforce the importance of continuing to explore new strategies for this challenging disease.” Dr. Hatoum continued, “What makes this approach particularly promising is its adaptability. Because the FDA-approved RenovoCath device administers chemotherapy directly near the tumor, it can continue to be integrated with a systemic therapy protocol regardless of how standard systemic treatment evolves in the future, this provides a versatile platform that can remain relevant as new chemotherapy regimens and targeted therapies emerge.” “I am proud to be part of the Phase III trial evaluating IAG, working alongside an exceptional multidisciplinary team committed to advancing care for patients with LAPC. Together, we are developing innovative treatment strategies that have the potential to improve outcomes and quality of life for our patients. Beyond pancreatic cancer, this novel platform also offers hope for expanding targeted regional chemotherapy delivery to other cancers, potentially opening new therapeutic opportunities across multiple solid tumors,” concluded Dr. Hatoum. “Completing enrollment in the Phase III TIGeR-PaC trial marks a major milestone for RenovoRx,” said Ramtin Agah, M.D., Executive Chairman, Chief Medical Officer, and Founder of RenovoRx. “TIGeR-PaC is the cornerstone of our clinical development program, and we are now closer than ever in our efforts to validate IAG and its efficacy through rigorous, long-term evaluation. We thank the participating clinical sites, the patients and their families for their dedication, support, and trust in this important study. With enrollment complete, we are now focused on advancing toward completion and data analysis. We believe TIGeR-PaC will provide meaningful additional validation of our TAMP therapy platform in an area with significant unmet need and limited therapeutic progress. The validation of this approach both in terms of tolerability and efficacy should provide additional tools for clinicians to offer patients in this challenging disease.” The study’s enrollment was supported by participation from nationally recognized cancer centers and academic medical institutions across the United States, including Johns Hopkins Medicine, University of Pittsburgh Medical Center, UT Southwestern Medical Center, University of Nebraska Medical Center, Baptist Health South Florida, Stephenson Cancer Center at the University of Oklahoma, and more. The study has also progressed through two independent interim analyses triggered following the 26 th event in 2023 and the 52 nd event in 2025, with the study’s independent Data Monitoring Committee (DMC) recommending continuation of the trial on both occasions. Together, these accomplishments reflect the successful execution of RenovoRx’s lead clinical program and support continued evaluation of its proprietary TAMP therapy platform. About RenovoCath Based on its FDA clearance, RenovoCath ® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf . About the TIGeR-PaC Clinical Trial TIGeR-PaC is an ongoing Phase III randomized multi-center trial evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). RenovoRx’s first investigational drug-device combination product candidate, using the TAMP therapy platform enabled with the Company’s FDA-cleared RenovoCath ® device, is designed for the intra-arterial administration of chemotherapy, gemcitabine (IAG). About RenovoRx, Inc. RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a standalone device. For its first full year of commercial efforts in 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales and a record $563,000 of sales in the first quarter of 2026. RenovoRx is actively working to expand the number of medical institutions initiating new RenovoCath orders, including esteemed, high-volume National Cancer Institute-designated centers. RenovoRx is also evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath, (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, which is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. Full enrollment in the TIGeR-PaC trial was achieved in August 2026, with completion of the trial currently expected during the first half of 2027. Initial topline data readout is expected during the second half of 2027. The IAG combination product candidate, enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA. For more information, visit . Follow RenovoRx on LinkedIn , X and Facebook . Cautionary Note Regarding Forward-Looking Statements This press release and statements of the Company’s management made in connection therewith described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including the anticipated timing for completion of and data readout from the Phase III TIGeR-PaC trial as described herein, (ii) the potential for our product candidates (including IAG) to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to commercialize RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our TAMP therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “aim,” “goal,” “estimates,” “intends,” and “potential,” or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about the future, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial sales efforts for RenovoCath and our TAMP technology may not lead to viable, revenue-generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs (including, most importantly, the timing for completion of and data readout from our Phase III TIGeR-PaC trial); (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals, including any New Drug Applications (including for IAG) which may be submitted to the FDA in the future); (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our ability to obtain additional capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xviii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we time to time with the Securities and Exchange Commission, which can be accessed at . Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law. Investor Contact : KCSA Strategic Communications Valter Pinto or Jack Perkins T: 212-896-1254 RenovoRx@KCSA.com Media Contact : STiR Communications Hannah Williams T: 803-521-1214 hannah@stir-communications.com

Phase 3Orphan Drug

100 Deals associated with Albumin-Bound Paclitaxel

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced breast cancer	China	CSPC Ouyi Pharmaceutical Co., Ltd.	10 Jun 2026
Neoplasms	Uruguay	Kexing Biopharm Co., Ltd.	31 Oct 2025
Metastatic Pancreatic Cancer	Peru	Zhejiang Haichang Bio-Tech Co., Ltd.	14 May 2025
Pancreatic Cancer	China	Bristol Myers Squibb Co.	05 Jan 2024
Pancreatic adenocarcinoma metastatic	United States	Teva Pharmaceuticals, Inc.	11 May 2023
Pancreatic carcinoma non-resectable	Japan	Taiho Pharmaceutical Co., Ltd.	18 Dec 2014
Stomach Cancer	Japan	Taiho Pharmaceutical Co., Ltd.	21 Feb 2013
Breast Cancer	China	Abraxis BioScience, Inc.	30 Jun 2008
Non-Small Cell Lung Cancer	European Union	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Non-Small Cell Lung Cancer	Iceland	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Non-Small Cell Lung Cancer	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Non-Small Cell Lung Cancer	Norway	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Pancreatic adenocarcinoma	European Union	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Pancreatic adenocarcinoma	Iceland	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Pancreatic adenocarcinoma	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Pancreatic adenocarcinoma	Norway	Bristol-Myers Squibb Pharma EEIG	11 Jan 2008
Metastatic breast cancer	United States	Bristol Myers Squibb Co.	07 Jan 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Gastric Adenocarcinoma	Phase 3	China	CSPC Ouyi Pharmaceutical Co., Ltd.	01 Mar 2020
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Argentina	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Chile	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Czechia	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	France	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Hungary	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Italy	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Mexico	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Peru	Hoffmann-La Roche, Inc.	10 Dec 2019
PD-L1 positive Triple Negative Breast Cancer	Phase 3	Poland	Hoffmann-La Roche, Inc.	10 Dec 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04243616 (CemiHALT, CTgov)	Phase 2	Invasive Mammary Carcinoma	36	Paclitaxel+Cyclophosphamide+Carboplatin+Cemiplimab+Doxorubicin	vndwmffntm = ocovqhtfax sljufpeokc (xxhcoadhgt, giicaflulx - oxmakngynp) View more	-	27 Jul 2026
NCT03410030 (AA NABPLAGEM, CTgov)	Phase 1/2	Pancreatic Ductal Adenocarcinoma \| Neoplasm Metastasis \| Metastatic Pancreatic Cancer	17	Ascorbic Acid (Ascorbic Acid 25 g/m^2)	psmhxxckgs(aponfswsym) = smfgumjcmv ywhbbpqjqs (fqpztwudjk, 66.3) View more	-	23 Jul 2026
NCT03410030 (AA NABPLAGEM, CTgov)	Phase 1/2		17	Ascorbic Acid (Ascorbic Acid 37.5 g/m^2)	psmhxxckgs(aponfswsym) = fkchqgjhnv ywhbbpqjqs (fqpztwudjk, 62.0) View more	-	23 Jul 2026
NCT04669197 (CTgov)	Phase 2	Pancreatic adenocarcinoma \| Pancreatic Ductal Adenocarcinoma \| Locally Advanced Pancreatic Adenocarcinoma	19	Paclitaxel protein bound+Hydroxychloroquine+Gemcitabine+cisplatin	oaovewtipj = zhngcjgxjk kjhtbqaegs (ufdpinkwih, kqxozoakvx - zvxqxtkdfp) View more	-	21 Jul 2026
NCT04216472 (CTgov)	Phase 2	Triple Negative Breast Cancer \| Hormone refractory breast cancer	6	Nab-paclitaxel+Alpelisib	mqzzcikoyf = rgtyjqwbpk xdcgmftpru (bjgvqeehlq, umuymjislb - bvabmcrwbt) View more	-	07 Jul 2026
ESMO_GI2026 \| ESMO_GCC2026	Not Applicable	Esophageal Carcinoma	91	chemoradiotherapy (CRT)	icuwltikue(butuybfjjc) = eftetpoobg llcthppqhx (yaotznqlwc ) View more	Positive	02 Jul 2026
ESMO_GI2026 \| ESMO_GCC2026	Not Applicable	Esophageal Carcinoma	91	chemoradiotherapy (CRT) (Surgery)	icuwltikue(butuybfjjc) = nemgmalfzr llcthppqhx (yaotznqlwc ) View more	Positive	02 Jul 2026
ESMO_GI2026 \| ESMO_GCC2026	Not Applicable	Metastatic Pancreatic Cancer First line BRCA1 \| BRCA2	26	Gemcitabine plus nab-paclitaxel (GnP)	eogflmihxn(pttrilhccb) = tbwtxutwfm xzpjocfpnl (ewyojaapqf ) View more	Positive	02 Jul 2026
ESMO_GI2026 \| ESMO_GCC2026	Not Applicable	Metastatic Pancreatic Cancer First line BRCA1 \| BRCA2	26	modified FOLFIRINOX (mFFX)	eogflmihxn(pttrilhccb) = yajrcdfpdf xzpjocfpnl (ewyojaapqf ) View more	Positive	02 Jul 2026
NCT03716180 (DAPHNe, Pubmed \| JAMA Oncol)	Phase 2	Neoadjuvant ERBB2-positive	98	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab (THP) (Stage II to III ERBB2-Positive Breast Cancer)	riezqngzsa(flhkolupgs) = avvzuiqfyj shapngnuis (fkpsanfzsn, 97 - 100) View more	Positive	25 Jun 2026
NCT03885219 (Pubmed \| Signal Transduct Target Ther)	Phase 2	Locally Advanced Pancreatic Adenocarcinoma First line	60	Nab-paclitaxel plus S-1	yqbepzxsgw(irxokzjryf) = nksrwaspzs dgvuuyfhzg (yfwsjsfrfk, 57.6 - 80.9) View more	Positive	22 Jun 2026
ESMO_GCC2026	Not Applicable	Endometrial Carcinoma	82	Adjuvant Paclitaxel and Carboplatin (Sequential therapy)	mxlgnduqft(eugladrqso) = wobbxwcfqe osadohrsla (lrufjfbagt ) View more	Positive	18 Jun 2026
NCT03138720 (Pubmed \| Oncologist)	Phase 2	Pancreatic Cancer Neoadjuvant	32	nab-paclitaxel + cisplatin + gemcitabine + paricalcitol	vhlfytbpyg(lgckjsmgyk) = wijewryzpi xlunrtfkxm (kevzlnkscj ) View more	Positive	06 Jun 2026
NCT03138720 (Pubmed \| Oncologist)	Phase 2	Pancreatic Cancer Neoadjuvant	32	nab-paclitaxel + cisplatin + gemcitabine + paricalcitol	vhlfytbpyg(lgckjsmgyk) = anwthhkjfx xlunrtfkxm (kevzlnkscj ) View more	Positive	06 Jun 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis